Delphi Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.15M | Sell |
5,302
-1,418
| -21% | -$315K | 1.38% | 36 |
|
|
2025
Q4 | $1.53M | Sell |
6,720
-210
| -3% | -$47.8K | 1.49% | 22 |
|
|
2025
Q3 | $1.6M | Buy |
6,930
+1,323
| +24% | +$269K | 1.49% | 10 |
|
|
2025
Q2 | $1.04M | Sell |
5,607
-398
| -7% | -$74K | 1.01% | 71 |
|
|
2025
Q1 | $1.26M | Sell |
6,005
-615
| -9% | -$120K | 1.28% | 52 |
|
|
2024
Q4 | $1.18M | Sell |
6,620
-73
| -1% | -$13.4K | 1.14% | 63 |
|
|
2024
Q3 | $1.32M | Sell |
6,693
-1,225
| -15% | -$229K | 1.2% | 58 |
|
|
2024
Q2 | $1.36M | Buy |
7,918
+12
| +0.2% | +$1.99K | 1.11% | 63 |
|
|
2024
Q1 | $1.44M | Sell |
7,906
-1,351
| -15% | -$233K | 1.12% | 61 |
|
|
2023
Q4 | $1.12M | Buy |
9,257
+1,316
| +17% | +$192K | 1.03% | 64 |
|
|
2023
Q3 | $1.18M | Buy |
7,941
+16
| +0.2% | +$2.35K | 1.21% | 56 |
|
|
2023
Q2 | $1.07M | Buy |
+7,925
| New | +$1.16M | 1.11% | 60 |
|
|
2022
Q4 | $1.32M | Buy |
+8,159
| New | +$1.25M | 1.6% | 16 |
|
|
2021
Q4 | $1.63M | Buy |
12,054
+396
| +3% | +$46.8K | 1.54% | 5 |
|
|
2021
Q3 | $1.26M | Buy |
11,658
+126
| +1% | +$14.4K | 1.29% | 22 |
|
|
2021
Q2 | $1.3M | Buy |
11,532
+236
| +2% | +$26.6K | 1.24% | 28 |
|
|
2021
Q1 | $1.22M | Buy |
+11,296
| New | +$1.21M | 1.3% | 34 |
|
|
2019
Q3 | $1.02M | Sell |
13,453
-408
| -3% | -$28K | 0.99% | 59 |
|
|
2019
Q2 | $1.01M | Sell |
13,861
-20
| -0.1% | -$1.57K | 0.91% | 65 |
|
|
2019
Q1 | $1.12M | Sell |
13,881
-4,524
| -25% | -$370K | 1.04% | 59 |
|
|
2018
Q4 | $1.7M | Buy |
18,405
+476
| +3% | +$41.9K | 1.54% | 28 |
|
|
2018
Q3 | $1.7M | Sell |
17,929
-592
| -3% | -$56.1K | 1.09% | 57 |
|
|
2018
Q2 | $1.71M | Sell |
18,521
-3,726
| -17% | -$364K | 1.05% | 61 |
|
|
2018
Q1 | $2.11M | Sell |
22,247
-5,498
| -20% | -$604K | 1.28% | 44 |
|
|
2017
Q4 | $2.68M | Sell |
27,745
-5,204
| -16% | -$490K | 1.53% | 20 |
|
|
2017
Q3 | $2.93M | Sell |
32,949
-104
| -0.3% | -$7.92K | 1.64% | 6 |
|
|
2017
Q2 | $2.4M | Sell |
33,053
-7,814
| -19% | -$525K | 1.33% | 33 |
|
|
2017
Q1 | $2.66M | Buy |
40,867
+3,051
| +8% | +$192K | 1.52% | 8 |
|
|
2016
Q4 | $2.37M | Buy |
37,816
+1,068
| +3% | +$65.2K | 1.38% | 24 |
|
|
2016
Q3 | $2.32M | Sell |
36,748
-3,390
| -8% | -$219K | 1.44% | 20 |
|
|
2016
Q2 | $2.48M | Sell |
40,138
-1,821
| -4% | -$111K | 1.59% | 10 |
|
|
2016
Q1 | $2.4M | Buy |
41,959
+1,161
| +3% | +$64.7K | 1.44% | 18 |
|
|
2015
Q4 | $2.42M | Sell |
40,798
-114,057
| -74% | -$6.57M | 1.56% | 12 |
|
|
2015
Q3 | $8.43M | Buy |
154,855
+2,945
| +2% | +$192K | 1.32% | 34 |
|
|
2015
Q2 | $10.2M | Buy |
151,910
+32,425
| +27% | +$2.12M | 1.37% | 17 |
|
|
2015
Q1 | $7M | Buy |
+119,485
| New | +$7.22M | 0.93% | 71 |
|
Other funds holding ABBV
VCM
VPM
Delphi Management's ABBV Position: Q1 2026 in Review
Delphi Management reduced its AbbVie (ABBV) stake by 21% in Q1 2026, selling an estimated $315K and leaving 5,302 shares worth $1.15M. The position accounts for 1.38% of the portfolio, ranked #36.
Delphi Management first reported a position in ABBV in Q1 2015 and has held it in 36 quarters since. The position peaked at $10.2M in Q2 2015. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Delphi Management held 5,302 shares of AbbVie worth $1.15M as of Q1 2026.
- Delphi Management sold 1,418 AbbVie shares in Q1 2026, an estimated $315K.
- AbbVie made up 1.38% of Delphi Management's portfolio in Q1 2026, its #36 holding.
- Delphi Management first reported a position in AbbVie in Q1 2015 and has held it in 36 quarters since.
- Delphi Management's AbbVie position peaked at $10.2M in Q2 2015.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Delphi Management's 13F filing for Q1 2026, filed 20 Apr 2026.